- Calcium & bone metabolism
- Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone
-
Lars Rejnmark
-
Endocrinol Metab. 2024;39(2):262-266. Published online April 4, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.1916
-
-
 Abstract
 PDF PubReader  ePub
- The conventional treatment of hypoparathyroidism (HypoPT) includes active vitamin D and calcium. Despite normalization of calcium levels, the conventional treatment is associated with fluctuations in calcium levels, hypercalciuria, renal impairment, and decreased quality of life (QoL). Replacement therapy with parathyroid hormone (PTH)(1-84) is an option in some countries. However, convincing beneficial effects have not been demonstrated, which may be due to the short duration of action of this treatment. Recently, palopegteriparatide (also known as TransCon PTH) has been marketed in Europe and is expected also to be approved in other countries. Palopegteriparatide is a prodrug with sustained release of PTH(1-34) designed to provide stable physiological PTH levels for 24 hours/day. A phase 3 study demonstrated maintenance of normocalcemia in patients with chronic HypoPT, with no need for conventional therapy. Furthermore, this treatment lowers urinary calcium and improves QoL. Another long-acting PTH analog with effects on the parathyroid hormone receptor (eneboparatide) is currently being tested in a phase 3 trial. Furthermore, the treatment of autosomal dominant hypocalcemia type 1 with a calcilytic (encaleret) is also being tested. All in all, improved treatment options are on the way that will likely take the treatment of HypoPT to the next level.
- Adrenal gland
- Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone
-
Lars Rejnmark, Line Underbjerg, Tanja Sikjaer
-
Endocrinol Metab. 2015;30(4):436-442. Published online December 31, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.4.436
-
-
3,494
View
-
39
Download
-
11
Web of Science
-
11
Crossref
-
Abstract
PDFPubReader
Hypoparathyroidism (HypoPT) is characterized by low serum calcium levels caused by an insufficient secretion of parathyroid hormone (PTH). Despite normalization of serum calcium levels by treatment with activated vitamin D analogues and calcium supplementation, patients are suffering from impaired quality of life (QoL) and are at increased risk of a number of comorbidities. Thus, despite normalization of calcium levels in response to conventional therapy, this should only be considered as an apparent normalization, as patients are suffering from a number of complications and calcium-phosphate homeostasis is not normalized in a physiological manner. In a number of recent studies, replacement therapy with recombinant human PTH (rhPTH(1-84)) as well as therapy with the N-terminal PTH fragment (rhPTH(1-34)) have been investigated. Both drugs have been shown to normalize serum calcium while reducing needs for activated vitamin D and calcium supplements. However, once a day injections cause large fluctuations in serum calcium. Twice a day injections diminish fluctuations, but don't restore the normal physiology of calcium homeostasis. Recent studies using pump-delivery have shown promising results on maintaining normocalcemia with minimal fluctuations in calcium levels. Further studies are needed to determine whether this may improve QoL and lower risk of complications. Such data are needed before replacement with the missing hormone can be recommended as standard therapy. -
Citations
Citations to this article as recorded by  - Point-of-Care Peptide Hormone Production Enabled by Cell-Free Protein Synthesis
Madison A. DeWinter, Ariel Helms Thames, Laura Guerrero, Weston Kightlinger, Ashty S. Karim, Michael C. Jewett
ACS Synthetic Biology.2023; 12(4): 1216. CrossRef - Comparing laser speckle contrast imaging and indocyanine green angiography for assessment of parathyroid perfusion
Emmanuel A. Mannoh, Naira Baregamian, Giju Thomas, Carmen C. Solόrzano, Anita Mahadevan-Jansen
Scientific Reports.2023;[Epub] CrossRef - Effects of Multi-stage Procurement on the Viability and Function of Human Donor Parathyroid Glands
Yvonne M. Kelly, Casey Ward, Run Zhang, Shareef Syed, Peter G. Stock, Quan-Yang Duh, Julie A. Sosa, James Koh
Journal of Surgical Research.2022; 276: 404. CrossRef - Kidney Complications and Hospitalization in Patients With Chronic Hypoparathyroidism: A Cohort Study in Sweden
Oskar Swartling, Marie Evans, Tim Spelman, Wafa Kamal, Olle Kämpe, Michael Mannstadt, Ylva Trolle Lagerros, Sigridur Björnsdottir
The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4098. CrossRef - Hypocalcaemia
Zaki Hassan-Smith, Neil Gittoes
Medicine.2021; 49(9): 562. CrossRef - Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
Michael Mannstadt, Bart L Clarke, John P Bilezikian, Henry Bone, Douglas Denham, Michael A Levine, Munro Peacock, Jeffrey Rothman, Dolores M Shoback, Mark L Warren, Nelson B Watts, Hak-Myung Lee, Nicole Sherry, Tamara J Vokes
The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5136. CrossRef - Management of Endocrine Emergencies in the ICU
Judith Jacobi
Journal of Pharmacy Practice.2019; 32(3): 314. CrossRef - Microencapsulated parathyroid allotransplantation in the omental tissue
Emrah Yucesan, Harun Basoglu, Beyza Goncu, Fahri Akbas, Yeliz Emine Ersoy, Erhan Aysan
Artificial Organs.2019; 43(10): 1022. CrossRef - Die HypAus-Studie
Maximilian Zach, Adelina Tmava-Berisha, Stefan Schatzl, Michael Lehner, Greisa Vila, Karin Amrein
Journal für Klinische Endokrinologie und Stoffwechsel.2018; 11(2): 45. CrossRef -
Sustained release of parathyroid hormone via
in situ
cross‐linking gelatin hydrogels improves the therapeutic potential of tonsil‐derived mesenchymal stem cells for hypoparathyroidism
Yoon Shin Park, Yunki Lee, Yoon Mi Jin, Gyungah Kim, Sung Chul Jung, Yoon Jeong Park, Ki Dong Park, Inho Jo
Journal of Tissue Engineering and Regenerative Medicine.2018;[Epub] CrossRef - Hypocalcaemia
Zaki Hassan-Smith, Neil Gittoes
Medicine.2017; 45(9): 555. CrossRef
|
KES
